Skip to main content
Premium Trial:

Request an Annual Quote

HBIO s Revenues Stay Flat, Earnings Shrink in Q2

NEW YORK, July 30 (GenomeWeb News) - Harvard Bioscience yesterday reported flat revenues and dwindling earnings for the second quarter.

 

The company's revenues for the quarter totaled $22.5 million, compared to $22.4 million during the same period last year.

 

"In the first half of this year our Genomic Solutions product lines produced disappointing results that have dragged down our overall growth and profitability so far this year," said CEO Chane Granziano in a company statement. "We have made significant changes in managing this business that we believe...will return this business to profitability and growth."

 

R&D expenses for the quarter remained flat at $1.7 million, similar to last year's costs.

 

HBIO's net income was $0.3 million, or $.01 per share, down from $0.74 million, or $.02 per share, for last year's quarter.

 

As of  June 30, HBIO had $10.5 million in cash and cash equivalents.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.